For most of 2026, the bear case on Eli Lilly came down to one thing: pricing pressure would destroy the math. Lower GLP-1 prices, thinner margins, slowing growth. The bears made it sound inevitable.
Then July 1 arrived.
That’s the date the Medicare GLP-1 Bridge program went live – a new CMS short-term demonstration that lets eligible Medicare Part D patients access certain GLP-1 weight-loss drugs for a $50 monthly copay. Lilly’s stock jumped more than 7% in a single session late last month just on the announcement. The access expansion didn’t just counter the pricing fear. It changed the fundamental question investors should be asking – which is no longer “will pricing hurt volume?” but “how large does this market actually get?”
The Numbers Behind the Story
Q1 2026 results were the kind of quarter that resets expectations. Revenue hit $19.8 billion – up 56% year-over-year. Non-GAAP EPS of $8.55 beat consensus by nearly 26%. Management raised full-year guidance to $82–$85 billion in revenue and lifted the profit forecast to $35.50–$37.00 per share. The low end of the new guidance range is higher than the prior high end.
Mounjaro, Lilly’s tirzepatide therapy for type 2 diabetes, generated about $8.7 billion in the quarter – up 125% from Q1 2025. Zepbound, the obesity version of the same compound, added about $4.16 billion, up roughly 79% year-over-year. These aren’t incremental gains. They’re the numbers of a franchise in full commercial acceleration.
What’s interesting is that these figures don’t yet reflect any meaningful contribution from Foundayo.
The Oral GLP-1 Changes Everything
In April, the FDA approved Foundayo – Lilly’s once-daily oral GLP-1 pill for chronic weight management. It can be taken any time of day, without food or water restrictions. That last detail is not trivial: the competing oral option from Novo Nordisk has specific timing requirements around meals.
The early commercial signals are encouraging. CVS Caremark said it will cover Foundayo, a development that would put Lilly’s obesity portfolio in coverage across the three largest U.S. pharmacy benefit managers. And Phase 3 data showed orforglipron outperforming oral semaglutide on both blood sugar control and weight loss in a head-to-head comparison in adults with type 2 diabetes.
The strategic logic is simple: injectable GLP-1s have a ceiling defined by patient reluctance around needles. Pills remove that barrier entirely. Analysts at Citi have argued the ease-of-use advantage of Foundayo more than offsets any efficacy differential versus Novo’s pill option, and that Lilly could capture a dominant share of the oral market as it scales.
- Q1 2026 revenue: $19.8B, +56% YoY
- Mounjaro Q1 sales: ~$8.7B, +125% YoY
- Zepbound Q1 sales: ~$4.16B, +~79% YoY
- Full-year 2026 revenue guidance: $82B–$85B
- 2026 EPS guidance: $35.50–$37.00 per share
The Medicare Wildcard
The GLP-1 Bridge program that started July 1 deserves more attention than it’s getting. Medicare covers tens of millions of Americans. Until now, obesity drugs were explicitly excluded from Medicare Part D coverage under a statute dating back to 2003. The Bridge program is a temporary demonstration, not a permanent policy change – but it opens the door to a patient population that was structurally inaccessible to GLP-1 manufacturers.
The commercial mechanics: eligible beneficiaries can access certain covered GLP-1 weight-loss drugs (including Zepbound and Foundayo) for a $50 monthly copay. If even a fraction of eligible Medicare patients enroll, the volume impact on Lilly’s second-half numbers could be significant. Lilly’s next earnings call is scheduled for August 5 – and that’s when prescription run-rate data for the Bridge program will start becoming visible.
That’s the real event to watch. Not the quarterly revenue beat. The script velocity coming out of Medicare.
The Competitive Picture
Novo Nordisk is losing ground. While both companies are dealing with U.S. pricing pressure tied to voluntary pricing agreements with the Trump administration, their 2026 outlooks are moving in opposite directions. Novo has guided for a sales decline. Lilly is guiding for 45%+ revenue growth. The divergence reflects Lilly’s stronger product profile, its early move into direct-to-consumer sales, and the commercial traction of tirzepatide’s superior clinical profile versus semaglutide.
Lilly is also not resting on the GLP-1 franchise alone. The pipeline now includes Kisunla for early Alzheimer’s, retatrutide in late-stage trials for obesity with additional cardiometabolic benefits, and a growing oncology portfolio. Estimates for 2026 EPS have been revised upward multiple times in recent months. Estimates for 2027 have also moved higher.
What the Bears Are Still Watching
Valuation is the honest concern. LLY trades at roughly 30x forward earnings – above the industry average, though below its own five-year mean. At ~$1,199 per share as of late June, the stock is about 3% from its 52-week high of $1,238. It’s not a deep value situation by any measure.
There’s also a policy risk that hasn’t fully resolved. The Bridge program is temporary. Permanent Medicare coverage for obesity drugs would require congressional action, and that timeline is uncertain. If the Bridge expires without a legislative follow-on, the access tailwind reverses.
And manufacturing at this scale is genuinely hard. Lilly has been adding capacity aggressively – including major expansions in Ireland and new manufacturing investments in Germany – but supply constraints have historically created friction between what the drug can sell and what can actually be shipped.
The Bigger Picture
Analysts estimate the global obesity drug market could reach $150 billion annually within a decade. Lilly and Novo currently split the majority of that market between them, with Lilly pulling ahead. The oral GLP-1 category is the next leg of that expansion – and Foundayo gives Lilly a genuine first-mover advantage in a format that could ultimately be larger than the injectable market it grew up in.
The bear case required pricing to eat the business alive. The Medicare program just complicated that argument significantly.
August 5 is when we find out if the patients actually showed up.
This article is for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own due diligence before making any investment decisions.
